Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis

por Hu, Hao, Lin, Wei Qing, Zhu, Qian, Yang, Xiong Wen, Wang, Hai Dong, Kuang, Yu Kang
Publicado 2016

Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis

por Hu, Hao, Zhu, Qian, Luo, Xian Shi, Yang, Xiong Wen, Wang, Hai Dong, Guo, Chang Ying
Publicado 2018

Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC

por Zhu, Qian, Hu, Hao, Jiang, Feng, Guo, Chang Ying, Yang, Xiong Wen, Liu, Xi, Kuang, Yu Kang
Publicado 2017

Sublobectomy for stage IA1‐2 invasive lung adenocarcinoma with consolidation tumor ratio ≤ 0.25

por Qi, Yi‐Fan, Qiu, Zhen‐Bin, Zhang, Chao, Fu, Rui, Yang, Xiong‐Wen, Chu, Xiang‐Peng, Chen, Zi‐Hao, Yang, Xue‐Ning, Wu, Yi‐Long, Zhong, Wen‐Zhao
Publicado 2022